-
EP3641814
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3641814
| EP3641814 - USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 27.03.2020 Database last updated on 03.06.2024 | |
| Former | The international publication has been made Status updated on 31.12.2018 | Most recent event Tooltip | 27.06.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Medicenna Therapeutics Inc. 200-1920 Youge Street Toronto, ON M4S 3E2 / CA | [2020/18] | Inventor(s) | 01 /
FIDAI, Shafique 1500 West Georgia Street Vancouver, BC V6G 2Z6 / CA | 02 /
MERCHANT, Fahar 2601-699 Cardero Street Vancouver, BC V6G 3H7 / CA | [2020/18] | Representative(s) | Kehoe, Laura Ellen, et al Keltie LLP No.1 London Bridge London SE1 9BA / GB | [2020/18] | Application number, filing date | 18820803.7 | 19.06.2018 | [2020/18] | WO2018IB00760 | Priority number, date | US201762521957P | 19.06.2017 Original published format: US 201762521957 P | US201862679687P | 01.06.2018 Original published format: US 201862679687 P | [2020/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018234862 | Date: | 27.12.2018 | Language: | EN | [2018/52] | Type: | A1 Application with search report | No.: | EP3641814 | Date: | 29.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.12.2018 takes the place of the publication of the European patent application. | [2020/18] | Search report(s) | International search report - published on: | CA | 27.12.2018 | (Supplementary) European search report - dispatched on: | EP | 26.05.2021 | Classification | IPC: | A61K39/395, A61K38/20, A61P35/00, C07K14/55, C07K16/28 | [2020/18] | CPC: |
C07K14/55 (EP,US);
A61K38/1709 (EP,US);
A61K38/2013 (EP,US);
A61K39/0011 (EP,US);
A61K39/39541 (EP,US);
A61K39/3955 (US);
A61P35/00 (EP,US);
C07K14/76 (US);
C07K16/2818 (EP,US);
C07K16/283 (US);
C07K16/2896 (US);
C07K19/00 (US);
C12N7/00 (US);
A61K2039/505 (EP,US);
A61K2039/5256 (US);
A61K2039/55533 (US);
A61K35/76 (EP,US);
C07K2317/76 (EP,US);
C07K2319/30 (EP,US);
C07K2319/31 (EP,US);
C12N2710/10034 (US);
C12N2710/10043 (US);
C12N2710/24134 (US);
C12N2710/24143 (US);
Y02A50/30 (EP)
(-)
| C-Set: |
A61K38/1709, A61K2300/00 (US,EP);
A61K38/2013, A61K2300/00 (US,EP);
A61K39/39541, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/18] | Title | German: | VERWENDUNGEN UND VERFAHREN FÜR IL-2-SUPERAGONISTEN, AGONISTEN UND FUSIONEN DAVON | [2020/18] | English: | USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF | [2020/18] | French: | UTILISATIONS ET PROCÉDÉS POUR DES SUPERAGONISTES ET AGONISTES D'IL-2 ET DES FUSIONS DE CEUX-CI | [2020/18] | Entry into regional phase | 17.01.2020 | National basic fee paid | 17.01.2020 | Search fee paid | 17.01.2020 | Designation fee(s) paid | 17.01.2020 | Examination fee paid | Examination procedure | 17.01.2020 | Examination requested [2020/18] | 22.12.2021 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 29.06.2020 | Renewal fee patent year 03 | 28.06.2021 | Renewal fee patent year 04 | 27.06.2022 | Renewal fee patent year 05 | 27.06.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2012119093 (UNIV LELAND STANFORD JUNIOR [US], et al) [Y] 1-9 * Paragraphs 16, 10 and 12 *; | [Y] - HUANG ET AL, "Abstract: 396PD : IL -2 synergizes with PD-1/PD-L1 blockade via CD 28/CHK1 pathway to enhance CD 81 T cell responses in lung squamous cell carcinoma", ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, (20161220), vol. 27, no. suppl 9, ISSN 0923-7534, XP009518574 [Y] 1-9 * the whole document * | International search | [Y]US9428567 (GARCIA KENAN CHRISTOPHER [US], et al) [Y] 4-6 and 9-19 * . whole document *; | [Y] - LEVIN, A.M. et al., "Exploiting a natural conformational switch to engineer an interleukin-2 superkine", Nature, (20121026), vol. 484, ISSN 0028-0836, pages 529 - 533, XP055214333 [Y] 1-19 * . whole document * DOI: http://dx.doi.org/10.1038/nature10975 | [Y] - CARMENTATE, T. et al., "Human IL -2 mutein with higher anti-tumor efficacy than wild type IL -2", Journal of Immunology, (20130515), vol. 190, ISSN 1550-6606, pages 6230 - 6238, XP002745304 [Y] 4 and 6-19 * . whole document * DOI: http://dx.doi.org/10.4049/jimmunol.1201895 | [Y] - HUANG, S. et al., "IL -2 synergizes with PD-1/PD-L1 blockade via CD 28/CHK1 pathway to enhance CD 81 T cell responses in lung squamous cell carcinoma", Annals of Oncology, (20161220), vol. 27, no. 9, ISSN 0923-7534, XP009518574 [Y] 1-19 * . whole document * |